(333 days)
K953239/A5
No
The summary describes a standard in vitro diagnostic assay for measuring CK-MB levels using an inhibition method and a specific analyzer. There is no mention of AI, ML, or any computational analysis beyond standard quantitative determination and statistical analysis of performance.
No
This device is an in vitro diagnostic test used for the kinetic quantitative determination of a specific enzyme activity, not for treating a disease or condition.
Yes
The "Intended Use / Indications for Use" section explicitly states that the assay is an "in vitro diagnostic test" used for the determination of CK-MB isoenzyme activity, which is then used for the "diagnosis and follow-up of AMI (acute myocardial infarction) and some muscular diseases."
No
The device is an in vitro diagnostic assay (CKMB UDR assay) used on a specific hardware system (UniCel DxC 600 System) to measure a substance in biological samples. It is not a software-only device.
Yes, this device is an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The "Intended Use / Indications for Use" section explicitly states that the CKMB UDR assay is an in vitro diagnostic test.
- Sample Type: It is used for the determination of CK-MB activity in serum and Liheparin plasma, which are biological samples taken from the body.
- Purpose: The assay is used for the kinetic quantitative determination of CK-MB, which is a measurement performed outside of the living organism to provide information about a person's health status (specifically, for the diagnosis and follow-up of AMI and muscular diseases).
- Professional Use: It is intended for professional use only, which is typical for IVD devices used in clinical laboratories.
N/A
Intended Use / Indications for Use
The CKMB UDR assay is an in vitro diagnostic test used for the kinetic quantitative determination on Unicel DxC 600 System of the CK-MB isoenzyme activity of creatine kinase in serum and Liheparin plasma by inhibition method. The assay is intended for professional use only. Creatine Kinase (CK) catalyses the reversible phosphorylation of creatine by ATP. CK is a dimer composed of two subunits which form three active isoenzymes: BB (CK-1), MB (CK-2), MM (CK-3). CK-BB isoenzyme only rarely appears in serum.
Elevated CK values are due to muscular damages and associated pathologies. CK determination, usually performed with CK2 (also called CK-MB), is used for the diagnosis and follow-up of AMI (acute myocardial infarction) and some muscular diseases.
Product codes (comma separated list FDA assigned to the subject device)
JHW, JIX
Device Description
Anti CK-M mouse monoclonal antibodies in the reagent 1 inhibit the CK-M subunit in the sample without affecting the CK-B subunits. The CK-B activity is determined by the CK-NAC method and corresponds to half the CK-MB activity.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
Not Found
Intended User / Care Setting
professional use only.
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Comparative performance studies were conducted using the UniCel DxC 600 Synchron System. Sentinel CKMB UDR assay on UniCel DxC 600 System yielded comparable performances to the Roche CK-MB (K003158) on Roche/Hitachi Modular P800 Analyzer (K953239/A5).
Method comparison: Sentinel CKMB UDR assay on UniCel DxC 600 System was compared to predicate device Roche CK-MB (K003158) on Roche/Hitachi Modular P800 by testing 306 human sera samples. This comparison showed a correlation coefficient (r) of 0.999, slope of 0.96, and intercept of 2.40 U/L.
Imprecision: Precision studies were conducted by using CKMB UDR on the UniCel DxC 600 System. The found %CV values for 20-day Inter-assay Imprecision were:
Human sera pool #1 (N=40, Mean=10.7 U/L): Total Imprecision SD=0.45 U/L, CV%=4.2; Within run SD=0.45 U/L, CV%=4.2
Human sera pool #2 (N=40, Mean=19.0 U/L): Total Imprecision SD=0.49 U/L, CV%=2.6; Within run SD=0.49 U/L, CV%=2.6
Human sera pool #3 (N=40, Mean=25.4 U/L): Total Imprecision SD=0.50 U/L, CV%=2.0; Within run SD=0.50 U/L, CV%=2.0
Human sera pool #4 (N=40, Mean=33.4 U/L): Total Imprecision SD=1.21 U/L, CV%=3.6; Within run SD=1.21 U/L, CV%=3.6
Spiked Human sera pool (N=40, Mean=584.1 U/L): Total Imprecision SD=5.11 U/L, CV%=0.9; Within run SD=3.76 U/L, CV%=0.6
Analytical Measurement Range (AMR): The found lower limit of the AMR of CKMB UDR on the UniCel DxC 600 System was 7.4 U/L. The found upper limit of the AMR was 600.0 U/L. The claimed AMR will be 9.0 to 600.0 U/L.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Correlation coefficient (r) of 0.999, slope of 0.96, and intercept of 2.40 U/L for method comparison.
%CV values for 20-day Inter-assay Imprecision ranging from 0.9% to 4.2%.
Analytical Measurement Range (AMR) of 9.0 to 600.0 U/L.
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
K953239/A5
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 862.1215 Creatine phosphokinase/creatine kinase or isoenzymes test system.
(a)
Identification. A creatine phosphokinase/creatine kinase or isoenzymes test system is a device intended to measure the activity of the enzyme creatine phosphokinase or its isoenzymes (a group of enzymes with similar biological activity) in plasma and serum. Measurements of creatine phosphokinase and its isoenzymes are used in the diagnosis and treatment of myocardial infarction and muscle diseases such as progressive, Duchenne-type muscular dystrophy.(b)
Classification. Class II.
0
AUG 1 9 2011
510(k) Summary
K102706 Summary page 1 of 4
| Name of Submitter and details | SENTINEL CH. SpA Via Robert Koch, 2 20152 Milan - Italy 39 02 34551448 Fax: 39 02 34551464 |
|---|---|
| Contact Person | Fabio Rota Technical Director +39 02 34551448 Fax: +39 02 34551464 |
| Date of Preparation of this Summary: | August 18th, 2011 |
| Trade Name: | CKMB UDR Assay |
| Classification Name: | Creatine phosphokinase/creatine kinase or isoenzymes test system. |
| Device Classification product code Subsequent Product Code | JHW / JIX |
| Regulation number/Class | 862.1215 / Class II |
This summary of 510(k) safety and effectiveness information is being submitted in accordance with the requirements of SMDA 1990 and 21 CFR 807.92. The assigned 510(k) number is: __K102706.
Test Description:
Anti CK-M mouse monoclonal antibodies in the reagent 1 inhibit the CK-M subunit in the sample without affecting the CK-B subunits. The CK-B activity is determined by the CK-NAC method and corresponds to half the CK-MB activity.
1
K102706 Summary page 2 of 4
Substantial Equivalence:
The CKMB UDR assay is substantially equivalent to Roche CK-MB assay (K003158). Both assays yield similar Performance Characteristics.
Similarities: . Both assays are used for the quantitative determination of CKMB . Both assays are based on immunologic inhibition of the CK-M subunit of Human Creatine kinase . Both assays are based on the same Immunological key materials: anti CK-M mouse monoclonal antibodies, which are bought from Roche. . Both assays are based on the Kinetic measurement of the CK-B subunit of the human Creatine Kinase . Both assays do have 340 nm as main wavelength . Both assays utilize reagents in R1 and R2 Liquid format. Both assays are based on human Serum and Li-heparin ● Plasma. . Both assays yield similar clinical results.
Differences:
- . The predicate device assay recommends the use of EDTA plasma specimens. Sentinel assay recommends the use of serum and Li-Heparin plasma only.
2
Intended Use:
The CKMB UDR assay is an in vitro diagnostic test used for the kinetic quantitative determination on Unicel DxC 600 System of the CK-MB isoenzyme activity of creatine kinase in serum and Liheparin plasma by inhibition method. The assay is intended for professional use only.
Performance Characteristics:
Comparative performance studies were conducted using the UniCel DxC 600 Synchron System. Sentinel CKMB UDR assay on UniCel DxC 600 System yielded comparable performances to the Roche CK-MB (K003158) on Roche/Hitachi Modular P800 Analyzer (K953239/A5).
Method comparison
Sentinel CKMB UDR assay on UniCel DxC 600 System was compared to predicate device Roche CK-MB (K003158) on Roche/Hitachi Modular P800 by testing 306 human sera samples. This comparison showed a correlation coefficient (r) of 0.999, slope of 0.96, and intercept of 2.40 U/L.
Conclusions
The generated data demonstrated an acceptable correlation between the CKMB UDR assay on the UniCel DxC 600 System vs. the Roche CKMB (K003158) on Roche/Hitachi Modular P800 Analyzer.
Imprecision
Precision studies were conducted by using CKMB UDR on the UniCel DxC 600 System. The found %CV values for 20-day Inter-assay Imprecision were:
3
K102706 Summary page 4 of 4
| | N | Mean
(U/L) | Total Imprecision | | Within run | |
|------------------------|----|---------------|-------------------|-----|-------------|-----|
| | | | SD (U/L) | CV% | SD
(U/L) | CV% |
| Human sera pool #1 | 40 | 10.7 | 0.45 | 4.2 | 0.45 | 4.2 |
| Human sera pool #2 | 40 | 19.0 | 0.49 | 2.6 | 0.49 | 2.6 |
| Human sera pool #3 | 40 | 25.4 | 0.50 | 2.0 | 0.50 | 2.0 |
| Human sera pool #4 | 40 | 33.4 | 1.21 | 3.6 | 1.21 | 3.6 |
| Spiked Human sera pool | 40 | 584.1 | 5.11 | 0.9 | 3.76 | 0.6 |
Analytical Measurement Range (AMR)
The found lower limit of the AMR of CKMB UDR on the UniCel DxC 600 System was 7.4 U/L. The found upper limit of the AMR was 600.0 U/L. The claimed AMR will be 9.0 to 600.0 U/L.
Conclusions for 510(k) Summary
Method comparison, Imprecision and AMR data demonstrate that the analytical performance of the CKMB UDR on the UniCel DxC 600 Synchron System is substantially equivalent to Roche CK-MB (K003158) on the Roche/Hitachi Modular P800 Analyzer
4
Image /page/4/Picture/0 description: The image shows the text "DEPARTMENT OF HEALTH & HUMAN SERVICES". The text is in all caps and is in a serif font. The text is centered in the image and is the only element in the image. The text is likely the header of a document or website.
Public Health Service
Food and Drug Administration 10903 New Hampshire Avenue Silver Spring, MD 20993
SENTINEL CH SpA c/o Fabio Rota Via Robert Koch 20152 Milan, Italy
Re: K102706
AUG 1 9 2011
Trade/Device Name: CKMB UDR Assay Regulation Number: 21 CFR 862.1215 Regulation Name: Creatine phosphokinase/creatine kinase or isoenzymes test system. Regulatory Class: Class II Product Code: JHS Dated: August 10, 2011 Received: August 12, 2011
Dear Mr. Rota:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into class II (Special Controls), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820). This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
5
Page 2 -
If you desire specific advice for your device on our labeling regulation (21 CFR Parts 801 and 809), please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (301) 796-5450. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free no mber (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html.
Sincerely yours.
C.C.
Courmey Harper, Ph.D. Director Division of Chemistry and Toxicology Office of In Vitro Diagnostic Device Evaluation and Safety Center for Devices and Radiological Health
: « » »
Enclosure
6
Indications for Use
510(k) Number (if known): K102706
Device Name: CKMB UDR
Indications for Use:
The CKMB UDR assay is an in vitro diagnostic test used for the kinetic quantitative determination on Unicel DxC 600 System of the CK-MB isoenzyme activity of creatine kinase in serum and Liheparin plasma by inhibition method. The assay is intended for professional use only. Creatine Kinase (CK) catalyses the reversible phosphorylation of creatine by ATP. CK is a dimer composed of two subunits which form three active isoenzymes: BB (CK-1), MB (CK-2), MM (CK-3). CK-BB isoenzyme only rarely appears in serum.
Elevated CK values are due to muscular damages and associated pathologies. CK determination, usually performed with CK2 (also called CK-MB), is used for the diagnosis and follow-up of AMI (acute myocardial infarction) and some muscular diseases.
Prescription Use X (Part 21 CFR 801 Subpart D)
:
AND/OR
Over-The-Counter Use (21 CFR 801 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE OF NEEDED)
Concurrence of CDRH, Office of In Vitro Diagnostic Device Evaluation and Safety (OIVD)
Rute Chube
Division Sign-Off Office of In Vitro Diagnostic Device Evaluation and Safety
510(k) K102706
page 1 of 1